

Index

Note: Page numbers in *italics* and **bold** refers to figures and tables, respectively.

a

- AAV mouse model of HBV (AAV-HBV) 189
- abacavir (ABC) 4, 135
- absorption, distribution, metabolism, and excretion (ADME) 51, 371, 455
- absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) 433
- early evaluation of *in vitro* 433
- acquired immunodeficiency syndrome (AIDS) 103, 127, 448
- active triphosphate 352
- acute-disease RNA viruses 413
- acute RNA respiratory viruses 11–14, **13**
- acyclic nucleoside phosphonate (ANP) 4, 132, 448
- acyclovir 77–79, 77
 - chemical pathway of 78
 - high-dose IV 80
- adefovir (AFV) 9
- adeno-associated virus (AAV) 189
- adenosine kinase (AK) 392
- adenosine monophosphate (AMP) 398
- adenoviruses (AdVs) 447, 449, 463
 - adenovirus type and response to BCV 466–467, **466**, **467**
 - ATHENA study 468–469, **468**
 - clinical experience with oral BCV for AdV 464–466
 - resistance to BCV 467
- adverse events (AEs) 283, 402
- AdV species C type 5 (AdVC5) 463
- Aedes* mosquitoes 428
- AiCuris 38–39, 52, 55
- alanine aminotransferase (ALT) 215
- allogeneic hematopoietic cell transplant (allo-HCT) 449
- 2'- α -F, 2'- β -C-methyl cytidine nucleoside (PSI-6130) 248–250, 249
 - in vitro* potency and rat pharmacokinetic study of **251**
 - metabolic profile of 252
- Alzheimer's disease (AD) 477–478
- amenamevir, 77 78
- amine in presatovir 323
- amino azetidine 316
- angiotensin-converting enzyme 2 (ACE2) 367
- animal models
 - of BCV 456, 459–460
 - RSV 319–320
 - of SARS-CoV-2 infection 417
- Animal Rule 459
 - scaling to humans 461–462
- animal studies
 - antiviral activity in humanized mice 150–151
 - antiviral activity in rhesus macaques 151–152
 - with EFdA 149, **155–159**
 - long-acting activity in various animals 152–160
 - for papillomavirus-associated tumors 480
 - pharmacokinetic studies in rodents 149
- antibody-dependent enhancement of infection (ADE) 428
- anti-CMV drug development 38–39
- antigenomic RNA 413
- antiproliferative activity of BCV 478–483
 - antiproliferative MOA 483
 - EBV-associated tumors 481–482
 - glioblastoma 482–483
 - papillomavirus-associated tumors 479–481
- antiretroviral therapy (ART) 4, 103, 127
- anti-SARS-CoV-2 drugs 390, 404
- antiviral activity
 - against double-stranded DNA viruses 450–453

Trends in Antiviral Drug Development, First Edition. Edited by Michael J. Sofia and Zhengqiang Wang.

© 2025 Wiley-VCH GmbH. Published 2025 by Wiley-VCH GmbH.

- antiviral activity (*continued*)
 - against RNA viruses 453–454
 - of BCV 450–454
 - of ensitrelvir 374–384
 - imdsiran 197–200
 - of molnupiravir 412–413
 - of VV116 398
 - antiviral drugs
 - acute RNA respiratory viruses 11–14, **13**
 - hepatitis B virus 9–10, **9**
 - hepatitis C virus 11, **12**
 - hepatitis D virus 10, **10**
 - human herpesviruses 2–4, **3**
 - human immunodeficiency virus 4, **5–6**
 - integrase strand transfer 7
 - new trends and challenges 15–16
 - protease 6–7
 - reverse transcriptase 4–6
 - SARS-CoV-2 14–15
 - viral capsid 8
 - viral entry 7–8
 - viral infections 1–2
 - antiviral pharmacology of RDV 343–348
 - antiviral prophylaxis 37–38
 - antiviral resistance
 - of LET 35–37, **36**
 - of RDV 351–353
 - structural model of SARS-CoV-2 RdRp 352
 - antiviral success of zidovudine 134
 - ARO-HBV/JNJ-3989 217
 - chronic hepatitis B virus infection 211, 212–215
 - clinical studies in chronically HBV-infected patients 220–238
 - development of RNAi therapeutics 216–217
 - discussion and perspectives 238–239
 - pharmacokinetics and safety in humans 218–220
 - asialoglycoprotein receptor (ASGPR) 189, 190
 - aspartic acid residues 6
 - atazanavir (ATV) 7
 - ATHENA study 468–469, **468**
 - Atripla 15
 - attachment inhibitors 127
 - azabicyclic ring inhibitor 275–276, 275
- b**
- baloxavir marboxil (BXM) 14
 - benzimidazole ribonucleoside (BDCRB) 46, **47**
 - Betacoronavirus* 367
 - bictegravir (BIC) 7
 - biochemical assay 336
 - biochemical mechanisms of inhibition 141–142
 - EFdA mechanisms of inhibition 142
 - BKV-associated nephropathy (BKVAN) 474
 - bovine RSV (bRSV) 320
 - breast cancer resistance protein (BCRP) 382
 - brincidofovir (BCV) 16, 447
 - antiproliferative activity 478–483
 - antiviral activity against double-stranded DNA viruses 450–453
 - antiviral activity against RNA viruses 453–454
 - clinical development 457–476, **458–459**
 - current and potential indications for 449, **450**
 - future directions 483–484
 - key clinical pharmacology and safety considerations 454–457, 456
 - key points 448–449
 - neurodegenerative diseases 476–478
- c**
- Cabenuva 15
 - cabotegravir (CAB) 7
 - canine coronavirus (CCoV) 396
 - capsid assembly modulator (CAM) 202
 - capsid protein (CA) 8
 - capsid-targeting antivirals 127
 - cardiac disease 324
 - CCR5 antagonists 127
 - central nervous system (CNS) 447
 - Centre for Drug Design and Discovery (CD3) 429
 - cervical intraepithelial neoplasia (CIN) 480
 - chemistry, manufacturing, and controls (CMC) 39
 - Chinese hamster lung cells (CHL cells) 400
 - chiral chromatography 312
 - chronically HBV infected (CHB) 211
 - clinical course of HBV infection 215
 - clinical studies of patients 220–238
 - HBV structure and associated molecular and cellular biology 212–215
 - reduction of serum HBsAg, HBeAg, and HBV DNA in 218, 219
 - schematic representation of HBV transcripts 213
 - chronic hepatitis C infection (cHCV) 247
 - chronic lung disease 324
 - ciclesonide 365
 - cidofovir (CDV) 35, **36**, 37, 77, 78–79, 447–448
 - cidofovir-diphosphate (CDV-PP) 447
 - cidofovir monophosphate (CDV-P) 447
 - clevudine (CLV) 9
 - 3C-like protease (3CL^{pro}) 367–368, 403
 - X-ray co-structure with 371
 - clinical proof-of-concept
 - on CMV prophylaxis in HSCT recipient 52
 - credentials established 54
 - 3',5'-diisobutyrate ester prodrug RG7128 identification and 250–251, 250
 - eIND treatment of lung transplant with multiresistant CMV 53–54, 54

- Phase 2a clinical trial (AIC001-2-001) 52–53
- 5'-phosphoramidate uridine nucleotide prodrug development for 251–255
- Cobicistat (COBI) 7
- combination antiviral therapy for CMV 473
- combination therapies
 - for combating COVID-19 404
 - with EFdA 146–148, 147
 - of JNJ-3989 with immune modulation 233–235
- confirmation assays 430
- Coronaviridae family 333
- coronavirus disease 2019 (COVID-19) 334, 390, 411, 412
 - caused by SARS-CoV-2 virus 365
 - clinical development 349–351
 - oral COVID-19 agents available in Japan **366–367**
- cotton rat infection model 320
- countermeasures 333
- covalently closed circular DNA (cccDNA) 193, 212
- cyclosporin A (CsA) 60
- cytidine monophosphate kinase 1 (Cmpk1) 413
- cytochrome P450 3A (CYP3A) 382
- cytomegalovirus (CMV) 33, 447, 469
 - antiviral drugs 35–37, **36**
 - clinical experience with oral BCV for 469–471, 470
 - dominant treatment strategies 37–38
 - patient groups with high risk complications 34–35, 35
 - resistance to BCV 471–474
 - treatments availability before letermovir 35
 - unmet medical need 38
- cytopathic effect (CPE) 429–430
- d**
- daclatasvir (DCV) 257
- darunavir (DRV) 7
- delavirdine (DLV) 6
- delayed chain terminaton (DCT) 141–142, 141
- dengue hemorrhagic fever (DHF) 427
- dengue shock syndrome (DSS) 427
- dengue viruses (DENV) 427–428
 - biological characterization 436–438
 - clinical candidate, identification of 435–436
 - discovery and optimization of new dengue drugs for prophylaxis 429
 - early evaluation of *in vitro* ADME-Tox and *in vivo* PK properties 433
 - early SAR exploration 431–432
 - identification of Hit CIM020928 429–431
 - improving oral bioavailability 433–434
 - mosnodenvir efficacy in preclinical DENV infection models 438–440
 - preclinical candidates, identification of 434–435
 - safety profile and pharmacokinetics of mosnodenvir in humans 440
- 2'-deoxy-4'-C-cyano-2-fluoro-adenosine (CNFdA) **139**
- 2'-deoxy-4'-C-ethynyl-2-chloroadenosine (ECldA) **139**
- 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine (EFdA) **138**
- 2'-deoxy-4'-C-ethynyl-adenosine (EdA) **138**
- 2'-deoxyadenosine (dA) 133
- deoxycytidine triphosphate (dCTP) 449
- 2'-deoxyribonucleotide biosynthetic pathways 413, 414
- deuremidevir hydrobromide tablets 403
- deuteration 393
- 2',3'-didehydro-3'-deoxy-4'-C-ethynyl-2-fluoro-adenosine (EFd4A) **139**
- 2',3'-dideoxy-4'-C-ethynyl-2-fluoroadenosine (EFddA) **138**
- 2',3'-dideoxyinosine (ddI) **139**
- digoxin 382
- 3,4-dihydroquinazolines 38
- 3,4-dihydroxybenzohydroxamic acid (didox) 482
- 3',5'-diisobutyrate ester prodrug (RG7128) 250–251
 - chemical structures of 250
 - INFORM-1 study results **251**
 - in vitro* potency and rat pharmacokinetic study of **251**
- 4-dimethylaminopyridine (DMAP) 395
 - direct antiviral agents act on 389
- direct-acting antiviral drug (DAAD) 63, 429
- direct-acting antivirals (DAAs) 1, 11, 248, 267
- direct antiviral treatment approach
 - with JNJ-3989-based regimens 220
 - pharmacological response with short-term treatment 220–225, 221
 - REEF-1 clinical study 225–231
 - REEF-2 clinical study 232–233
- DNA synthesis by RT 130–131, 131
- 1-docosanol, 77 78–79
- dolutegravir (DTG) 7, 104
 - antiviral potency against integrase mutations **107**
 - antiviral profile of acyclic and bicyclic compounds **108**
 - clinical development 115
 - efficacy in Phase 3/3b studies **117**
 - enzyme and inhibition activity of early second-generation INSTIs 106
 - first-generation HIV-1 integrase strand transfer inhibitors 105
 - HIV-1 integrase stand transfer inhibitors 105
 - medicinal chemistry 105–111

- dolutegravir (DTG) (*continued*)
 monocyclic carbamoyl pyridone lead
 inhibitor 1, 109
 overview 103–104
 PK studies supported once-daily dosing of
 DTG 115–116
 six-membered ring tricyclic carbamoyl
 pyridones **110–111**
 structure–activity relationship of tricyclic
 rings **109**
 studies of individuals with prior treatment
 failure 119–120
 studies of people living with HIV-1 116–119
 virology 111–115
 dominant treatment strategies 37–38
 doravirine (DOR) 6, 160
 double-stranded DNA (dsDNA) 128, 447
 double-stranded DNA viruses
 antiviral activity against 450
 antiviral MOA 450–453
 double-stranded linear DNA
 (dsDNA) 212–213
 D-phenylglycine 284, **285**, **288–289**
 drug–drug interactions (DDI) 51, 271, 382
 drug metabolism and pharmacokinetics
 (DMPK) 369
 drug resistance 62–64, 64
 drugs targeting reverse transcriptase 4
- e**
 Ebola virus (EBOV) 338, 349, 453–454
 RDV in treatment of 390–391
 EBV nuclear protein 2 (EBNA2) 482
 effective concentration (EC₅₀) 82–83, 273
 efficient mismatched incorporation
 141–142, 141
 elvitegravir (EVG) 7
 Emergency Investigational New Drug
 (eIND) 53–54, 54, 453
 emergency use authorization (EUA) 390
 (+)-enantiomer 433, 434
 end of treatment (EOT) 282
 endosomal sorting complex required for
 transport (ESCRT) 128
 ensitrelvir 15, 366, 369
 antiviral activity of 374
 clinical trial of 382–384
 co-crystal structures of 374
 discovery of 369–374
 in vivo antiviral efficacy of 376–380
 pharmacokinetics 380–382
 profile of **375**
 timeline of discovery 385
 entecavir (ETV) 9
 Epclusa® 247, 260, 267, **268**
 epithelial lining fluid (ELF) 322, 322
 Epstein–Barr virus (EBV) 454
 EBV-associated tumors 481–482
 and multiple sclerosis 476–477
 4′-ethynyl-2-fluoro-2′-deoxyadenosine
 (EFdA) 4, 128, 160
 adenosine analogs, potency and
 selectivity **138–139**
 animal studies 149–166, **155–159**
 chemical structures of 132
 clinical trials 160, **161–165**
 combination therapies with EFdA 146–148
 compound modifications effects 137–144
 compound with 4′-ethynyl, 2-fluoro, and
 3′-hydroxy modifications 137–144
 development of 133–137
 DNA synthesis by RT 130–131, 131
 4′-ethynyl ribose modifications 134–135
 2-fluoro adenosine modifications 135
 3′-hydroxy ribose modification 136–137
 long-acting methods for 160–166
 mechanism of resistance/
 hypersusceptibility 144
 NRTTIs as drug class 166
 overview 127–128
 synthesis advances 148, 149
 viral hypersusceptibility mechanisms to 146
 viral resistance mechanisms to 144–146
 4′-ethynyl modification effects on EFdA
 137–140, 140
 4′-ethynyl ribose modifications 134–135
 etravirine (ETR) 6
 European Medicines Agency (EMA) 51, 324
 excision enhancement mutations (EEMs) 145
- f**
 famciclovir 77, 78
 favipiravir (FPV) 14, 15, 365, 413
 feline enteric coronavirus (FECV) 396
 feline infectious peritonitis virus
 (FIPV) 396
 fetal-bovine serum (FBS) 313
 fibroblast growth factor (FGF2) 478
 filoviruses 334
 filovirus outbreaks in West Africa 333
 fixed-dose combinations (FDCs) 1
 flaviviruses 333, 334, 412
 fluorine 274, 434
 2-fluoro adenosine modifications 135
 2′-fluoro modification effects on EFdA
 140–141, 141
 food effect on PKs of ensitrelvir
 381–382
 forward-looking approach 278
 fosamprenavir (FPV) 7
 foscarnet (FOS) 35, **36**, 37, 77, 78–79, 80
 fostemsavir (FTR) 8
 functional assessment of chronic illness
 therapy-fatigue score (FACET-F) 282

- functional assessment of chronic illness therapy-fatigue subscale (FACET-FS) 282
- fused-ring system 284
- fusion inhibitors 127
- fusion mechanism 312, 313, 318
- fusion protein (F) 310, 317
 - presatovir inhibits pre- to post-fusion transformation 319
- fusion-targeting enfuvirtide 8
- g**
- GagPol polyprotein precursor (Pr160^{Gag-Pol}) 128
- Gag polyprotein precursor (Pr55^{Gag}) 128
- GalNAc-conjugated siRNA 187
 - comparison of preclinical anti-HBV efficacy between LNP-siRNA and 188–190
 - structural components of 188
- ganciclovir (GCV) 35, 36–37, **36**, 41
- genetic diversity 271
- genital HSV 87–89
- Genotype 1 (GT1) HCV infection 267
- German Hepatitis C Cohort (GECCO) 299
- glecaprevir 11
- glioblastoma 482–483
- glycol series 434, 435
 - structure of compounds from 431
- glycoprotein (G) 310
- glycoprotein B (gB) 42
- graft-versus-host disease (GVHD) 469–470
- granulocyte colony-stimulating factor (G-CSF) 62
- grid inhomogeneous solvation theory (GIST) 372
- GS-441524 390
 - activation pathways of 392
 - derivatives and two prodrugs 393
 - deuterated derivative 393
 - structures of 391
- guinea pig model for genital HSV-2 infection 84
- h**
- H1N1 swine influenza pandemic 333
- HALT study
 - key data from **465**
 - at time of virologic failure 467
- Harvoni® 247, 260, 267, **268**, 270
- HBV models, imdusiran antiviral activity in 197–199
- HBV surface antigen (HBsAg) 211
 - HBsAg targeting siRNA JNJ-3989 in CHD 236
 - REEF-D clinical study 236–238
- head and neck cancer squamous cell carcinoma (HNSCC) 481
- helicase-primase inhibitor (HPI). *see* pritelivir
- hematopoietic cell transplant (HCT) 448
- hematopoietic stem cell transplant (HSCT) 324
- hemorrhagic cystitis (HC) 474
- hepatitis B virus (HBV) 1, 9–10, **9**, 15–16, 187
- hepatitis C virus (HCV) 1, 11, **12**, 15, 247, 267, 335, 368
 - electron study design 257
 - family 271
 - Phase 2 clinical study SVR results in genotype 1 patients **259**
 - Phase 2 clinical trial **256**
 - Phase 2 combination clinical study SVR results in genotype 1–3 patients **258**
 - Phase 3 studies in genotype 1–6 patients **259**
 - regimens include Sovaldi, Harvoni, Epclusa and Vosevi 260
 - sofosbuvir as backbone of HCV curative therapies 255–260
 - structure of SOF (PSI-7977) 256
- hepatitis delta virus (HDV) 187
- hepatitis D virus (HDV) 10, **10**
- hepatocellular carcinoma (HCC) 211, 268
- hereditary transthyretin amyloidosis (hATTR) 216
- herpes simplex encephalitis (HSE) 76
- herpes simplex virus (HSV) 1, 75, 477–478
 - clinical data 86–91
 - nonclinical data 82–86
 - resistant infections 77–81, 80
 - synopsis 93–94
 - treatment 76–79
 - virology and disease 75–76
- HHV5. *see* cytomegalovirus (CMV)
- highly active antiretroviral therapy (HAART) 4, 43, 476
- HIV-1
 - DTG clinical studies of people living with 116–119
 - first-generation HIV-1 integrase strand transfer inhibitors 105
 - integrase stand transfer inhibitors 105
- host genome
- HSV type 1 (HSV-1) 75–76
- HSV type 2 (HSV-2) 75–76
- human airway epithelial cultures (HAE) 337
- human angiotensin-converting enzyme 2 (hACE2) 396
- human coronaviruses (HCoVs) 396
- human cytomegalovirus (HCMV) 1
- human dose prediction for RSV inhibitors 323
- human herpesvirus 6 (HHV-6) 478
- human herpesviruses (HHVs) 1
 - antiviral drugs targeting 2–4, **3**
- human immunodeficiency virus (HIV) 1, 76, 103, 127, 368
 - antiviral drugs targeting 4, **5–6**, 15

- human immunodeficiency virus (HIV)
 - (*continued*)
 - replication cycle 128
 - structure and function of HIV RT 128–130
- humanized mice, EFdA antiviral activity
 - in 150–151
- human liver microsome (HLM) 275, 433
- human organic anion transporter 1 (hOAT1) 448
- human papillomavirus (HPV) 452, 479
- human stem cell transplant (HSCT)
 - patients 34, 35, 52
 - clinical development and real-world data 57
 - CMV prophylaxis marketing approval in recipients 57
 - CMV prophylaxis trial in 55–57, 58
 - first prophylaxis trial in 55, 56
 - follow-up trials in specific populations 59–60
 - Phase 3 trial for extension of prophylaxis period 59
 - prophylaxis trial marketing approval in recipients 57
- hydrodynamically injected HBV model (HDI HBV model) 217, 218, 219
- 3'-hydroxy modification effects on EFdA 141
- 3'-hydroxy ribose modification 136–137
- hypersusceptibility 144–149
- i**
- ibalizumab 8
- iDNA 213–214, 217–218
- idoxuridine (IDU) 1
- imdisiran
 - abrogation of siRNA immunostimulatory potential 192–193
 - activity
 - n primary mouse and human hepatocyte HBV models 197–199
 - activity of imdisiran against HBV variants **197**
 - antiviral activity 197
 - combination with standard of care and investigational agents 200–203, **203**
 - design and preclinical characterization 192
 - in vivo* antiviral activity 199–200
 - off-targeting analysis in PHH 196
 - perspectives 203–206
 - siRNA target site sequence 193–196, 193, **195**
- imiquimod 77, 78–79
- immediate chain termination (ICT) 132, 141–142, 141
- immunocompromised mouse model, pritelivir in 86
- immunocompromised patients 34, 89, 324
- indinavir (IDV) 7
- infectious antibody–virus complexes 428
- influenza A virus (IAV) 11, 13–14
- influenza B virus (IBV) 11, 13–14
- INFORM-1 study 251, **251**
- inhibition mechanisms of EFdA 141
 - biochemical mechanisms of inhibition 141–142
 - structural mechanisms of inhibition 142–144
- inhibitor classes of RT 131–133
 - chemical structures of EFdA, dA, TFV, and AZT 132
 - EFdA, novel NRTTI 133
 - NNRTIs 133
 - NRTIs 132–133
- integrase (IN) 7
- integrase strand transfer, drugs targeting 7
- integrase strand transfer inhibitor (INSTI) 4, 7, 103–104, 127
 - dissociation from integrase–DNA complexes **115**
 - dissociation from integrase proteins 113
 - enzyme and inhibition activity of early second-generation 106
- integrated HBV DNA 193
- intention-to-treat (ITT) 269, 382
- interferon (IFN) 247, 267
 - IFN-based therapies 268–269
 - interferon- α 11
- internalized RSV RNA 310–311
- intravaginal ring (IVR) 153
- intravenous formulation (IV formulation)
 - BCV for AdV 468
 - for CMV 52
 - for DENV 433
 - for Ebola 341
 - for FOS 37
- investigational new drug application (IND) 278
- in vitro* activity against
 - papillomavirus-associated tumors 479–480
- in vitro* anti-SARS-CoV-2 activity assay 392
- in vitro* antiviral activity of ensitrelvir 374
- in vitro* antiviral specificity and CMV 43
- in vitro* drug
 - combination profile 43
 - resistance studies 63
- in vitro* inhibition of both focal and high titer infections 43
- in vitro* metabolism of RDV 339–341, 340
- in vitro* potency
 - vs. clinical CMV isolates and resistance breaking profile 41–42, 42
 - vs. laboratory CMV strains 39–41, **40, 41**
- in vitro* studies for HSV-1 and HSV-2 82–84, 83
- in vivo* antiviral efficacy of ensitrelvir 376
 - delayed-treatment model 376–378
 - pharmacokinetics and pharmacodynamics 378–380

- in vivo* efficacy
 - and CMVs 42
 - testing in mice 436
- in vivo* lung metabolism of RDV 342–343
- in vivo* pharmacokinetics
 - properties for DENV 433
 - of RDV 341–342
- in vivo* studies for HSV 84–86
 - guinea pig model for genital HSV-2 infection 84, 85
 - mouse model for HSE 84–86, 85
 - pritelivir in immunocompromised mouse model 86
- islatravir (ISL). *see* 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)
- isobutyrate ester prodrugs 393
- isopropyl 337
- ivermectin 365
- j**
- Japan, oral COVID-19 agents available in 365, **366–367**
- JC virus (JCV) 474
 - clinical data with CDV/BCV 475–476
- JNJ-3989
 - combination approaches with immune modulation 233
 - PENGUIN clinical study 234
 - pharmacological response to 220–225, 221
 - pharmacokinetics and safety in humans 218–220
 - REEF-IT clinical study 234–235
 - siRNAs 217–218
- k**
- kidney transplantation (KT) patients
 - clinical development and real-world data 62
 - CMV prophylaxis and preemptive treatment in 60
 - LET for CMV prophylaxis in 60–61
 - LET marketing approval in recipients 61–62
 - Phase 3 noninferiority trial in 61
 - risks and benefits of LET vs. VGCV in 62
- l**
- lamivudine (3TC) 9, 10
- latent membrane protein 1 (LMP1) 481
- lead
 - identification 311–313
 - optimization 313–316
 - SAR of aryl substitutions on 314
 - SAR on pyrazolopyrimidine analogs 316
 - SAR on 5-substitution of pyrazolopyrimidine analogs 317
- ledipasvir (LDV) 271, **272**
 - differential end substitution with unsymmetric core 276
 - discovery of 270–278
 - early development of 278–280
 - fluorene-based core provides potency 274
 - LDV/SOF STR clinical trial results and real-world effectiveness 280–283, **281**
 - preclinical LDV PK curves 277
 - symmetric core bis-benzimidazole inhibitor potency 273
 - unsymmetric core imidazole-X-benzimidazole inhibitor potency 274
- lenacapavir (LEN) 8, 15, 160
- lens epithelium-derived growth factor (LEDGF) 7
- letermovir (LET) 33
 - antiviral potency/selectivity/inhibitory profile 39–43
 - clinical development and MAA/NDA submission 51
 - clinical proof-of-concept 52–54
 - for CMV prophylaxis in HSCT patients 55–60
 - for CMV prophylaxis in KT patients 60–61
 - CMV treatments before 35–38
 - credentials established 54
 - cytomegalovirus () 33
 - discovery phase 38–39
 - drug–drug interaction studies 51
 - drug resistance 62–64
 - inhibitory profile, characteristics of 43
 - IV formulation 52
 - mechanism of action studies 43
 - outlook for 65–66
 - patient groups with high risk complications 34–35, 35
 - Phase 1 trial 51–52
 - Phase 2a clinical trial (AIC001-2-001) 52–53
 - preclinical characterization 39–43
 - preclinical safety evaluation 50
 - real-world resistance 65
 - regulatory support for clinical development 51
 - resistance in clinical trials 64–65
 - resistance mutations 63–64, 64
 - special populations 51–52
 - terminase inhibitors 46–50, **47–48**
- lipid nanoparticle (LNP) 187
- lipophilic compounds 323
- lipophilic prodrugs 337
- LNP-siRNA 187
 - preclinical anti-HBV efficacy comparison between GalNAc-conjugated siRNA and 188–190
 - structural components of 188
- long-acting injectables (LAIs) 1
- long-acting therapy
 - of delivery for EFdA treatment 160–166
 - in various animals 152–160

- lopinavir (LPV) 7
- lost to follow-up (LTFU) 280
- lower respiratory tract infection (LRTI) 325
- lung distribution properties 322–323
- m**
- male genital tract (MGT) 151
- maraviroc (MVC) 8
- maribavir (MBV) 4, 471
- mechanism of action (MoA) studies 39, 43
 - antiproliferative 483
 - antiviral 451–453
 - in vitro* activity against
 - papillomavirus-associated tumors and 479–480
 - target identification 43–46, 44–46
- Medicines and Healthcare products Regulatory Agency (MHRA) 411
- Memphis 37b clinical strain (M37) 320
- Merkel cell carcinoma (MCC) 474
- Merkel cell polyomavirus (MCPyV) 474
- messenger RNA (mRNA) 212
- metformin 382
- methoxymethyl-carbamate (Moc) 272–273
- 1'-methyl analog 336
- Middle East respiratory syndrome coronavirus (MERS-CoV) 333
- minimal monitoring trial (MinMon trial) 299, 299
- minus-strand cDNA 130, 131
- mitochondrial RNA polymerase (POLRMT) 336
- 1'-modified C-nucleosides, discovery of 335–336
 - 1'-modified 4-aza-7, 9-dideazaadenosine C-nucleosides 335
- molnupiravir (MPV) 14, 366, 411
 - mechanism of antiviral activity 412–413
 - potential for NHC-TP incorporation into host genome 413–415
 - risk of molnupiravir-enhanced viral evolution 415–416
 - therapeutic benefit of 416–418
 - uptake and mechanism of action of 412
- monkeypox (mpox) 456
- monophenol mono-(L)-alanine ester
 - phosphoramidate prodrugs 337, 337
- 5'-monophosphate prodrug strategy 253–254
- mosnodenvir (JNJ-1802) 429, 436
 - efficacy in preclinical DENV infection models 438–440
 - safety profile and pharmacokinetics in humans 440
- mouse CMV (MCMV) 42
- mouse hepatitis virus (MHV) 396
- mouse model
 - for HSE 84–86
 - reduction of serum HBsAg, HBeAg, and HBV DNA in chronic HBV infection 218, 219
- mousepox model 460–461
- Mpox virus 463
- multiple sclerosis (MS) 474, 476–477
- multiplicities of infection (MOI) 43
- murine hepatitis virus (MHV) 351
- murine polyomavirus (MuPyV) 474
- n**
- N, N*-dimethylformamide dimethyl acetal (DMF-DMA) 395
- N*⁴-hydroxycytidine (NHC) 412
 - antiviral activity of 412
- N*-acetylgalactosamine-conjugated siRNAs 187
- National Medical Products Administration (NMPA) 403
- natural killer/T-cell lymphoma (NKTCL) 482
- natural monoacyl-phospholipids 448
- natural ribonucleotide triphosphates (NTPs) 343
- nelfinavir (NFV) 7
- neurodegenerative diseases 476
 - EBV and multiple sclerosis 476–477
 - HHV-6 478
 - HSV and Alzheimer's disease 477–478
- nevirapine (NVP) 6
- NHC diphosphate form (NHC-DP) 413
- nirmatrelvir 366, 368, 411
 - co-crystal structures of 374
- nirsevimab 310
- N*-methylpyrrolidone (NMP) 395
- no adverse effect level (NOAEL) 220
- noncoding control region (NCCR) 474
- nonhuman primates (NHPs) 342, 436
- non-nucleoside reverse transcriptase inhibitor (NNRTI) 4, 127, 133
 - drug class 166
- nonstructural protein 5A (NS5A) 270
 - crystal structures of 273
- nonstructural protein 5B (NS5B) 270
- nonstructural protein 14 (nsp14) 392
- no-observed-adverse-effect levels (NOAELs) 400
- normal bronchial epithelial cells (NHBE) 337
- N*-protein inhibitor (RSV604) 311
- nucleic acids 192, 334
- nucleoside 336
 - analogs 77–78
- nucleos(t)ide antiviral drugs
 - role in viral diseases treatment 389–390
 - targeting SARS-CoV-2 RdRp 403
- nucleoside reverse transcriptase inhibitors (NRTIs) 4–6, 5–6, 127, 132–133
 - NRTI discriminatory mutations 145
- nucleoside reverse transcriptase translocation inhibitor (NRTTI) 4

- nucleostide analogs (NA) 211
 nucleotides, chemical modification of 192
- o**
- obeldesivir
 clinical development 351
 oral delivery and discovery of 343
 Omicron pandemic period 384
 Omicron variant spread in China 402–403
 open reading frame (ORF) 212
 organic anion transporter (OAT) 382
 organic anion transporter 1 (OAT1) 455
 organic anion transporting polypeptide (OATP) 382
 organic cation transporter (OCT) 382
 orthopoxvirus 452, 457
 oseltamivir (OTV) 13
- p**
- Palivizumab 310
 pangenotypic NS5A inhibitor program
 discovery of velpatasvir 284–293
 initiation of 283–284
 papillomavirus 450
 papillomavirus-associated tumors 479
 animal studies 480
 clinical studies 480
 in vitro activity against
 papillomavirus-associated tumors and
 MOA 479–480
 paramyxoviruses 334
 pathogenic RNA viruses 334
 Paxlovid 14, 411, 417–418
 pediatric HSCT recipients 59–60
 pegylated interferon (PEG-IFN) 10, 247
 penciclovir 77–79, 77
 PENGUIN clinical study 234
 people living with HCV (PLWHCV) 269–270
 peramivir (PRV) 13–14
 P-glycoprotein (P-gp) 382
 pharmacokinetics (PK) 49, 51, 81, 103, 321, 429
 of ensitrelvir 380–382
 of mosnodenvir in humans 440
 preclinical intravenous and oral PK of
 presatovir 320–322, **321**
 of remdesivir 339–343
 and safety of JNJ-3989 in humans 218–220
 studies in rodents 149
 studies supported once-daily dosing of
 DTG 115–116, *116*
 of VV116 400–402, **401**, *402*
 Phase 1 trial
 of LET 51–52
 of pritelivir 86–87, *87*
 program 324–325
 of RDV 348–349
 Phase 2 clinical trials of pritelivir 87–89, *88*, *89*
 Phase 2 program 325–327
 Phase 2/3 PRIOH-1 clinical trials of
 pritelivir 89–90, *90*
 Phase 2a clinical trial 52–53
 Phase 2b first prophylaxis trial, in HSCT
 patients 55, *56*
 Phase 3 trial
 CMV prophylaxis trial in HSCT
 patients 55–57, *58*
 for extension of prophylaxis period 59
 noninferiority trial in KT recipients 61, *62*
 of pritelivir 89–90, *90*
 of VV116 402–403
 phenotypic high-throughput screening 81
 phosphoramidate 337
 phosphoramidate prodrugs 338, *391*
 optimization for RSV 336–338
 5'-phosphoramidate uridine nucleotide
 prodrug for liver targeting 251–255
 concept of liver targeting nucleotide
 prodrug 253
 design of compound assessment
 cascade 254
 metabolic profile of PSI-6130 252
 Phase 1b clinical study results of
 PSI-7851 **255**
 pibrentasvir 11
 picornavirus inhibition 412
 plaque-forming-unit equivalents (PFUe) 325
 plasma protein adjusted EC 50 (paEC
 50) 313
 plasma viral RNA 154
 plus-strand cDNA 130, *131*
 pneumoviruses 334
 polioviruses 413
 poly(ethylene glycol) (PEG) 188
 polymerase 389
 polymerase chain reaction (PCR) 76
 polyomaviruses (PyVs) 452, *474*
 BKV clinical data with CDV/BCV 474–475
 JCV clinical data with CDV/BCV 475–476
 polypurine tract (PPT) 130
 positive single-stranded RNA (+ssRNA) 128
 post-attachment inhibitors 127
 potential for NHC-TP incorporation
 into 413–415
 poxviruses 457–463
 preemptive therapy (PET) /preemptive
 treatment 37, *38*
 pre-exposure prophylaxis (PrEP) 1
 presatovir 309
 clinical development 323
 discovery of 311
 human dose prediction 323
 inhibitor of respiratory syncytial
 virus 309–311
 lead identification 311–313

- presatovir (*continued*)
- lead optimization 313–316
 - lung distribution properties 322–323
 - mechanism of action studies 317–319
 - pharmacokinetics 320
 - pharmacological profiling 317
 - Phase 1 program 324–325
 - Phase 2 program 325–327
 - preclinical intravenous and oral
 - pharmacokinetics 320–322
 - regulatory considerations 323–324
 - RSV animal models 319–320
 - spectrum of activity 320
 - treatment emergent mutations 327–328
- presatovir clinical development strategy 324
- primary human hepatocytes (PHH) 193
- primary human keratinocytes (PHKs) 479
- primary mouse HBV models (PMH) 197–199
- primer-binding site (PBS) 130
- pritelivir 77, 78
- discovery and target identification 81–82, 81
 - early access program cases 92
 - immunocompromised mouse model 86
 - mechanism of action 82
 - metabolism of 87
 - resistance 91–93
- 3'-processing (3'-P) 7
- prodrug strategy 312
- progressive multifocal leukoencephalopathy (PML) 474
- proof-of-concept (PoC) 52, 87, 89, 319
- prophylaxis 37–38
- protease 6–7
- protease inhibitor (PI) 4, 127
- protocol-defined virologic failure (PDVF) 118
- pyrimidinone 315
- q**
- quantitative RT-PCR (RT-qPCR) 430
- quinazoline 48
- r**
- rabbitpox model 460
- racemate 312, 434
- raltegravir (RAL) 7
- randomized controlled trial (RCT) 465
- rat CMV (RCMV) 42
- rat liver microsomes (RLMs) 433
- RdRp enzymes 343–344
- RDV monophosphate (RMP) 398
- reduced relapsing-remitting MS (RRMS) 476
- REEF-1 clinical study 225–231
- design 225
 - individual patient HBsAg over time 229
 - mean change in HBeAg 230
 - mean change in HBsAg 227
 - mean change in HBsAg over time 228
 - mean change in HBV RNA over time 231
 - percentages of patients meeting
 - NA-stopping criteria 226
- REEF-2 clinical study of ARO-HBV/ JNJ-3989 232–233, 233
- REEF-D clinical study of ARO-HBV/ JNJ-3989 236–238, 237
- REEF-IT clinical study of ARO-HBV/ JNJ-3989 234–235, 235
- relaxed circular DNA (rcDNA) 212
- remdesivir (RDV) 14, 312, 334–335, 390
- activation pathways of 392
 - antiviral pharmacology 343–348
 - antiviral resistance 351–353
 - clinical studies 348–351
 - discovery of 335, 390–394
 - 1'-modified C-nucleosides, discovery
 - of 335–336
 - for patients with moderate-to-severe
 - COVID-19 404
 - pharmacokinetics 339–343
 - phosphoramidate prodrug optimization for
 - RSV 336–338
 - structure of 334
 - synthesis 338–339, 339
- renal proximal tubule epithelial cells (RPTECs) 448
- resistance
- in clinical trials 64–65
 - genotyping 64
- resistance-associated mutations (RAMs) 452
- resistance-associated substitutions (RAS) 271
- resistant infections of HSV 77–81, 89–91
- therapeutic approach 80
- resistant/refractory CMV disease (R/R CMV disease) 469
- respiratory syncytia virus (RSV) 2, 16, 309, 336, 396
- animal models 319–320
 - fusion inhibitor 310
 - phosphoramidate prodrug optimization
 - for 336–338
 - presatovir inhibitor of 309–311
 - virion architecture and gene encoding 10
 - mRNA and 11 proteins 310
- reverse transcriptase (RT) 4–6, 128
- DNA synthesis by 130
 - HIV-1 RT process 131
 - inhibitor classes 132–133
 - structure and function of HIV RT 128–130
- rhesus macaques (RMs) 151
- EFdA antiviral activity in 151–152
- ribavirin (RBV) 11, 16, 310, 412–413
- ribonucleotide biosynthetic pathways 413, 414
- ribonucleotide reductase enzyme (RNR) 414
- rilpivirine (RPV) 6

- rimantadine (RIM) 13
R-isomer 312, 313
R-isomer amine 316
 ritonavir (RTV) 7
 RNA-dependent RNA polymerase
 (RdRp) 248, 312, 335,
 368, 398
 RNAi therapeutic ARO-HBV/JNJ-73763989
 development of 216
 RNAi as therapeutic modality 216
 siRNA to treat HBV infection 216–217
 RNA-induced silencing complex (RISC) 187
 RNA virus(es)
 antiviral activity against 453–454
 families 412
 rodents, pharmacokinetic studies in 149
 rosuvastatin 382
 RSV A2 human epithelial cell-based assay
 (HEp-2 cell-based assay) 336
- s**
- S*-adenosyl-L-homocysteine hydrolase
 (SAHase) 134, 136
S-amino pyrrolidine 316
 saquinavir (SQV) 7
 SARS-CoV-2 3CL pro inhibitor 369
 noncovalent inhibitor of 369
 structures of 369
 selectivity index (SI) 41
 severe acute respiratory syndrome coronavirus
 2 (SARS-CoV-2) 2, 14–15, 333–334,
 390, 411, 454
 COVID-19 pandemic caused by 365
 lifecycle of 368
 severe dengue 427
S/GSK1349572. *see* dolutegravir (DTG)
 SHIONOGI compound library 370, 371
 short interfering RNAs (siRNAs) 187
 abrogation of siRNA immunostimulatory
 potential 192–193
 comparison of siRNA activity against HBsAg
 and HBx targets 191–192
 imtusiran siRNA target site sequence
 193–196, 193, **195**
S-hydroxy analog 316
 simeprevir (SIM) 257
 single-stranded RNA virus in Flaviviridae
 family 267
 single-tablet regimens (STRs) 268, 271
S-isomer 312
 small interfering RNA (siRNA) 216
 JNJ-3989 cross-reactivity to HBV genotypes
 and transcripts 217–218
 reduction of serum HBsAg, HBeAg, and
 HBV DNA 218, 219
 to treat HBV infection 216–217
 small-molecule inhibitors 369
- smallpox
 non-replicating smallpox vaccine
 ACAM3000 462
 outbreaks 457
 resistance for 462
 sodium taurocholate cotransporting
 polypeptide (NTCP) 212
 sofosbuvir (SOF) 11, 247, 270, 391
 2'- α -F, 2'- β -C-methyl cytidine nucleoside
 PSI-6130 248–250, 249
 3',5'-diisobutyrate ester prodrug RG7128
 and clinical PoC 250–251, 250, **251**
 backbone of HCV curative
 therapies 255–260
 discovery of 247–248
 HCV genome, structural and nonstructural
 viral proteins 248
 LDV/SOF STR clinical trial results and
 real-world effectiveness 280–283, **281**
 5'-phosphoramidate uridine nucleotide
 prodrug 251–255, 252–254, **255**
 SOF-containing single-tablet regimens 268
 structure of 256
 synopsis 261
 solid organ transplant (SOT) 34, 35, 469
 Sovaldi® 260, 260
 standard of care (SoC) 53, 267
 strand transfer (ST) 7
 structural mechanisms of inhibition 142–144
 changes in EFdA-containing
 complexes 144
 EFdA-TP interactions at polymerase active
 site of RT/DNAddGMP/EFdA-TP 143
 structure–activity relationship (SAR) 38–39,
 39, 283, 336, 371, 372, 430
 early SAR exploration 431–432
 structure-based drug design 389
 sulfonamide **48**, 49
 sulfone series 431, 435
 Sunlenca 15
 sustained viral response (SVR) 269
 real-world IFN/ribavirin SVR rates 269
 syndrome coronavirus 2 (SARS-CoV-2) 411
 synthesis advances 148–149, 149
- t**
- Tamiflu 323
 target identification 43–46
 function of viral terminase complex 45
 in vitro inhibition of viral replication 44
 LET effect on viral DNA processing and
 packaging 46
 TCRB, **47** 49
 tecovirimat 16
 telbivudine (TBV) 9
 tenofovir (TFV) 4, 9, 136
 tenofovir alafenamide (TAF) 9, 10, 200, 391, 477

- tenofovir disoproxil fumarate (TDF) 10, 476–477
- terminase inhibitors
- advantages of 49–50
 - interaction between LET and terminase complex 49
 - previous and contemporary drug candidates 46–49, **47–48**
- thymidine-associated mutations (TAMs) 245
- thymidine kinase (TK) 77, 79–80
- time-of-addition assay (TOA assay) 312
- tipranavir (TPV) 7
- toxicology assessment of VV116 400
- transplant recipients. *see* letermovir (LET)
- treatment-emergent adverse events (TEAEs) 91, 384
- treatment-experienced group (TE group) 280
- treatment naive (TN) 280
- triazine 1, 371, 372
- hydration site analysis of X-ray co-structure of 372
 - structure-based optimization of hit compound 373
 - structure of 371
- Trichodysplasia Spinulosa Polyomavirus (TSPyV) 474
- tricyclic X groups 274–275
- triethylamine (Et₃N) 395
- tri-isobutyrate ester prodrug 394
- Type I pneumocytes in alveoli 309
- Type II pneumocytes in alveoli 309
- u**
- upper respiratory tract infection (URTI) 325
- uridine-cytidine kinases 1 and 2 (Uck1/Uck2) 413
- uridine monophosphate (UMP) 398
- US Food and Drug Administration (FDA) 51, 80, 324, 457
- v**
- vaccine interaction studies of BCV 462
- vaccinia virus 462–463
- valacyclovir, 77 78–79
- valganciclovir (VGCV) 35–37, **36**
- valpatasvir 11
- varicella zoster virus (VZV) 1, 75
- variola virus (VARV) 457
- vector control strategies 428
- velpatasvir (VEL) 271, **272**
- development of 293–296
 - discovery of 284–293, **291**
 - pangenotypic SOF/VEL STR 297–300
 - tetracyclic core with VEL end-groups **292**
- viral capsid 8
- viral diseases
- nucleos(t)ide antiviral drugs role in 389–390
 - RDV for 348
- viral DNA polymerases
- viruses with 451–452, 452
 - viruses without 452–453, 453
- viral entry, drugs targeting 7–8
- viral hypersusceptibility mechanisms 145, 146
- viral infections 1–2, 309
- viral load reduction (VLR) 278–279
- viral proteases 368
- viral proteins, direct antiviral agents act on 389
- viral resistance mechanisms 144–146
- mechanism of RT resistance or hypersusceptibility to EFdA-TP 145
- viral RNA (vRNA) 154
- “viral swarm” 271
- virology 111–115, 396
- in vitro* studies 111–115, **112**, **112**, **113**, **115**
 - virologic efficacy profile of DTG **112**
- viruses
- without viral DNA polymerases 452–453
 - with viral DNA polymerases 451–452
- Vosevi® 247, 260, **268**
- voxilaprevir 11
- VV116 390, 394
- antiviral potency of **397**
 - enzymatic biotransformation of VV116 398
 - future direction 403–404
 - identification of hydrobromide salt of X6 as 394
 - mechanism of antiviral activity of 398
 - pharmacokinetics 400–402
 - Phase III studies 402–403
 - preclinical pharmacokinetics 398–399
 - preclinical study 396
 - safety and tolerability 402
 - structures and non-deuterated counterpart 399
 - synthesis 394–396
 - toxicology 400
- VV116 nucleoside triphosphate (116-NTP) 398
- w**
- whole genome sequencing of virus populations 413
- x**
- xenotransplant model 41, 42
- z**
- zanamivir (ZAN) 13